Core Viewpoint - Aptose Biosciences Inc. has announced a plan to consolidate its outstanding common shares on a 1-for-30 basis to comply with Nasdaq's minimum bid price requirement and to attract a broader range of investors [1][2]. Group 1: Share Consolidation Details - The company currently has 64,301,183 common shares outstanding, which will be reduced to approximately 2,143,372 common shares post-consolidation [2]. - The reverse share split is subject to approval by the Toronto Stock Exchange and is expected to take effect on February 26, 2025 [2]. - No fractional common shares will be issued; any resulting fractions will be canceled without consideration [2]. Group 2: Shareholder Instructions - Registered shareholders will receive a Letter of Transmittal to facilitate the exchange of pre-reverse split common shares for post-reverse split shares [3]. - Shareholders holding shares through brokers will not need to complete a Letter of Transmittal [3]. Group 3: Impact on Securities - The exercise or conversion price and the number of common shares under outstanding warrants, convertible notes, and stock options will be proportionately adjusted to reflect the reverse share split [4]. Group 4: Company Overview - Aptose Biosciences is focused on developing precision medicines for oncology, particularly in hematology, with its lead product being the oral kinase inhibitor tuspetinib (TUS) [5]. - Tuspetinib is being developed as a frontline triplet therapy for newly diagnosed acute myeloid leukemia (AML) [5].

Core Viewpoint - Aptose Biosciences Inc. has entered into a common share purchase agreement with an institutional investor to raise capital for its clinical-stage oncology developments, particularly focusing on its lead drug tuspetinib for treating acute myeloid leukemia (AML) [1][5]. Group 1: Financing Agreements - The Committed Equity Facility agreement allows Aptose to sell and issue up to $25 million of its common shares over 24 months, subject to certain conditions and regulatory limitations [2]. - Aptose has also established a sales agreement for "at-the-market" (ATM) distributions on Nasdaq, with an aggregate offering price of up to $1 million [3]. Group 2: Company Overview - Aptose is a clinical-stage biotechnology company focused on developing precision medicines for unmet medical needs in oncology, with an emphasis on hematology [5]. - The company's lead product, tuspetinib (TUS), is being developed as a frontline triplet therapy for newly diagnosed AML and has shown efficacy as both a monotherapy and in combination therapy for relapsed or refractory AML [5].

Core Insights - The TUS+VEN+AZA triplet therapy has shown promising early results in achieving complete remission in newly diagnosed acute myeloid leukemia (AML) patients, particularly those with TP53 mutations [1][3] - The therapy demonstrates a favorable safety profile, with no need for dose adjustments of venetoclax (VEN) and azacitidine (AZA) [1][3] - The TUSCANY trial aims to establish this triplet as a frontline treatment for diverse AML populations, including those traditionally difficult to treat [4][5] Company Overview - Aptose Biosciences Inc. is a clinical-stage biotechnology company focused on developing precision medicines for oncology, with an emphasis on hematology [7] - The company's lead product, tuspetinib (TUS), is being evaluated as a frontline triplet therapy for newly diagnosed AML patients [7] Clinical Trial Details - The TUSCANY Phase 1/2 trial is designed to test various doses of TUS in combination with standard doses of AZA and VEN for AML patients ineligible for induction chemotherapy [5][6] - Initial data from the trial indicates that four newly diagnosed AML patients have received the lowest dose of TUS (40 mg), with two achieving complete remissions by the end of Cycle 1 [5][6] - Pharmacokinetic analyses show that TUS levels remain stable and unaffected by the addition of AZA, indicating predictable dosing without the need for adjustments [5]

Core Insights - The TUS+VEN+AZA triplet therapy has shown promising early results in achieving complete remission in newly diagnosed acute myeloid leukemia (AML) patients, particularly those with TP53 mutations [1][3][4] - The therapy demonstrates a favorable safety profile, with no need for dose adjustments of venetoclax (VEN) and azacitidine (AZA) during treatment [1][3][6] - The TUSCANY trial aims to establish this triplet as a frontline therapy for diverse AML populations, including those traditionally difficult to treat [4][5][8] Company Overview - Aptose Biosciences is a clinical-stage biotechnology company focused on developing precision medicines for oncology, particularly in hematology [8] - The company's lead product, tuspetinib (TUS), is being evaluated as a frontline triplet therapy for newly diagnosed AML patients [8] Trial Details - The TUSCANY Phase 1/2 trial is designed to test various doses of TUS in combination with standard doses of AZA and VEN for AML patients ineligible for induction chemotherapy [5] - The initial cohort received a starting dose of 40 mg of TUS, with plans for dose escalations based on safety reviews [5] - Enrollment is ongoing, with an expected 18-24 patients by mid to late 2025 [5] Early Results - Four newly diagnosed AML patients have been treated with the 40 mg dose of TUS, with three patients achieving complete remissions by the end of Cycle 1 [6] - Notably, a patient with biallelic TP53 mutations achieved complete remission, highlighting the potential of the therapy in challenging cases [6] - Pharmacokinetic analyses indicate that TUS levels remain stable and unaffected by the addition of AZA, suggesting predictability in dosing [6]

Core Viewpoint - Aptose Biosciences has initiated dosing for the first patients in the TUSCANY Phase 1/2 study, evaluating the triplet therapy of tuspetinib (TUS), venetoclax (VEN), and azacitidine (AZA) for newly diagnosed acute myeloid leukemia (AML) patients [1][2][3] Group 1: Study Details - The TUSCANY Phase 1/2 trial aims to establish an improved frontline therapy for newly diagnosed AML patients, focusing on safety, durability, and broad activity across diverse AML populations [2][4] - The trial will test various doses and schedules of TUS in combination with standard doses of azacitidine and venetoclax, with TUS starting at 40mg once daily in 28-day cycles [4] - Enrollment is expected to include 18-24 patients by mid to late 2025 across multiple U.S. sites [4] Group 2: Drug Efficacy and Safety - Previous APTIVATE trials indicated that TUS as a single agent and in combination with VEN showed favorable safety and broad activity in relapsed or refractory AML populations, including those with adverse mutations [2][3] - The triplet therapy is anticipated to deliver high response rates and longer survival for newly diagnosed AML patients while minimizing toxicities associated with other treatments [3] Group 3: Company Overview - Aptose Biosciences is a clinical-stage biotechnology company focused on developing precision medicines for oncology, particularly in hematology [6] - The lead clinical-stage oral kinase inhibitor, tuspetinib, has shown promise as both a monotherapy and in combination therapy for AML [6]

SAN DIEGO and TORONTO, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated targeted agents to treat hematologic malignancies, today announced that the Nasdaq Hearings Panel (“Panel”) has granted the Company’s request for an extension to evidence compliance with all applicable criteria for continued listing on The Nasdaq Stock Market. On or before March 31, 2025, the Compan ...

Peer-reviewed publication details unique TUS mechanism of action TUS+VEN combination synthetic lethality overcomes resistance to VEN Tuspetinib prolongs survival in multiple AML models resistant to other drugs Findings suggest TUS will demonstrate broad antileukemic activity across AML patients TUS+VEN+AZA Triplet Frontline Therapy in Newly Diagnosed AML Patients Now Enrolling SAN DIEGO and TORONTO, Dec. 12, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS ...

Core Viewpoint - Aptose Biosciences Inc. has successfully closed a public offering, raising $8 million through the sale of 40 million common shares at $0.20 each, along with warrants for an additional 20 million shares [1]. Group 1: Offering Details - The public offering included 40,000,000 common shares priced at $0.20 per share and warrants to purchase up to 20,000,000 common shares at an exercise price of $0.25 per share, which are exercisable immediately and will expire in five years [1]. - The offering was conducted by A.G.P./Alliance Global Partners as the sole placement agent [2]. - The gross proceeds from the offering amounted to $8 million before deducting fees and expenses [1]. Group 2: Use of Proceeds - The net proceeds from the offering are intended for working capital and general corporate purposes [1]. Group 3: Company Overview - Aptose Biosciences is a clinical-stage biotechnology company focused on developing precision medicines for oncology, particularly in hematology [5]. - The company's lead product, tuspetinib (TUS), is an oral kinase inhibitor that has shown efficacy as both a monotherapy and in combination therapy for patients with relapsed or refractory acute myeloid leukemia (AML) [5].

SAN DIEGO and TORONTO, Nov. 22, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, today announced the pricing of its "reasonable best efforts" public offering with participation from the CEO and existing and new healthcare focused investors for the purchase and sale of up to 40,000,000 shares of common stock and warrants to ...

Core Insights - The TUSCANY study has been initiated to evaluate the combination of tuspetinib (TUS), venetoclax (VEN), and azacitidine (AZA) for newly diagnosed acute myeloid leukemia (AML) patients [1][2] - Tuspetinib is positioned as a frontline therapy for AML, particularly for patients who are ineligible for intensive chemotherapy, and has shown favorable safety and broad clinical activity [2][3] - The trial aims to enroll 18-24 patients across 12 clinical sites in the U.S. by mid to late 2025, with a focus on various dosing schedules of TUS [4] Company Overview - Aptose Biosciences is a clinical-stage biotechnology company focused on developing precision medicines for hematologic malignancies, with a pipeline that includes tuspetinib and luxeptinib [6] - Tuspetinib is an oral kinase inhibitor that targets multiple kinases and has demonstrated efficacy both as a monotherapy and in combination therapy for relapsed or refractory AML [6] - The company aims to address unmet medical needs in oncology, particularly in hematology, by enhancing the efficacy of existing therapies without overlapping toxicities [6]